Hypha’s Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and our latest blogs
In our Q2 2023 newsletter we look at the synthesis of a prominent acyl glucuronide of the Mcl-1 inhibitor AZD5991, hydroxylated metabolites of the recently FDA approved rezafungin, as well as links to our latest blogs.
Sign up at the bottom of the page in the link here to receive our quarterly newsletter by email.
